The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Open accessAbstract
PURPOSE: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein. METHODS: The kinase inhibitory activity of netarsudil was compared to its esterase metabolite, netarsudil-M1, and 3 other ROCK inhibitors using a commercially available kinase assay kit. Disruption of actin stress fibers was measured in primary porcine TM cells and disruption of focal adhesions in transformed human TM (HTM) cells. Induction of fibrosis markers after exposure to transforming growth factor-β2 (TGF-β2) was conducted in primary HTM cells. Ocular hypotensive activity and tolerability of topical formulations were evaluated in normotensive Dutch Belted rabbits and Formosan Rock monkeys. In vitro corneal metabolism assays were conducted using dog, pig, rabbit, monkey, and human corneas. In vivo ocular pharmacokinetics was studied in Dutch Belted rabbits. RESULTS: s of 79 and 16 nM, respectively, and blocked the profibrotic effects of TGF-β2 in HTM cells. Netarsudil produced large reductions in IOP in rabbits and monkeys that were sustained for at least 24 h after once daily dosing, with transient, mild hyperemia observed as the only adverse effect. CONCLUSION: Netarsudil is a novel ROCK/NET inhibitor with high potency in biochemical and cell-based assays, an ability to produce large and durable IOP reductions in animal models, and favorable pharmacokinetic and ocular tolerability profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current management of glaucoma
Lusthaus, J., & Goldberg, I. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50020 · Cited by 354
Knipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells
Pattabiraman, P. P., & Rao, P. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2009 · Cited by 189
Self-citationPharmacological management of ocular hypertension: current approaches and future prospective
Bucolo, C., Salomone, S., Drago, F., Reibaldi, M., Longo, A., & Uva, M. G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.012 · Cited by 71
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Serle, J. B., Katz, L. J., McLaurin, E., Heah, T., Ramirez-Davis, N., Usner, D. W., Novack, G. D., & Kopczynski, C. C. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.11.019 · Cited by 269
Self-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna, A. P., & Johnson, M. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.040 · Cited by 257
Metadata
- Authors
- Lin, C.-W., Sherman, B., Moore, L. A., Laethem, C. L., Lu, D.-W., Pattabiraman, P. P., Rao, P. V., deLong, M. A., & Kopczynski, C. C.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-03
- Volume
- 34
- Issue
- 1-2
- Pages
- 40-51
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W2624866195
- Cited by
- 187
- References
- 4
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.